? CPDM, DSM, Women and Minorities, Lifespan The CPDM is the administrative home for support and monitoring of all clinical research conducted in the ACC regardless of the type of intervention or sponsor. The CPDM creates, directs and enforces the operational policies and expectations for the conduct of all cancer-related clinical research within the ACC across the University of Pennsylvania. The CPDM scope is of necessity broad, encompassing and implementing policies and procedures, education and training, supervision of data managers and research nurses, and oversight over the specialty clinical research units (CRUs) that are a vital part of our Center. The CPDM oversees first- stage and second-stage protocol review, manages our centralized clinical trials management system (Velos), performs monitoring and auditing of clinical trials, and manages the complex activities of our mandatory clinical research review committees. Key elements within the CPDM are the Department of Operations, Compliance and Monitoring (DOCM), the Protocol Review and Monitoring System (PRMS, known as the Clinical Trials Scientific Review and Monitoring Committee [CTSRMC]), the Data and Safety Monitoring Committee (DSMC), and Office of Legal Affairs, along with our disease and discipline-specialized CRUs. The DSMC is responsible for ensuring that all cancer-related human subjects studies abide by all Federal regulations and institutional policies as well as our NCI-approved ACC Data and Safety Monitoring Plan (DSMP) to ensure subject safety and study integrity. The DSMC complements yet functions completely independently of CTSRMC. The DSMC has independent oversight responsibility for all activated CTSRMC-approved protocols, serves as the parent committee for the ACC DSMP, and sets policies, standards and expectations for all aspects of monitoring, auditing and pharmacovigilance for adult and pediatric studies. Key initiatives in the current funding period include improved times for protocol activation (50% shorter compared to 2015), improved data tracking systems, enhanced operations of the CRUs, and a new leader and coordinator for NCTN trials. The result overall has been a 116% increase in average annual accruals to interventional trials during this funding period compared to the last (20% increase for treatment; 314% increase in non-therapeutic interventional). Ensuring the inclusion of Women and Minorities in clinical trials continues to be a central goal for the ACC, part of our commitment to address the cancer burden in minority and underserved populations in our catchment area. Extensive efforts during this funding period have resulted in exceptional representation of minorities on ACC clinical trials and doubling of the percentages of Black subjects enrolled on trials, now exceeding the percentage of Black patients seen at the ACC. Lifespan. The ACC supports participation of patients of all ages in clinical trials. Our CTSRMC will not approve protocols that exclude children or the elderly without a compelling rationale. We benefit from a fully embedded Pediatric Oncology Program that performs innovative clinical trials for nearly all childhood malignancies, with members who lead the pediatric National Group.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088756
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
EchevarrĂ­a-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5

Showing the most recent 10 out of 1047 publications